We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





Ultra-Fast, Fully Automated SARS-CoV-2 Virus Detection Test Uniquely Suited for Near Patient Testing

By LabMedica International staff writers
Posted on 28 Jul 2021
A fully automated SARS-CoV-2 virus detection test is believed to be one of the fastest tests in the world and is uniquely suited for near patient testing.

Developed by Curiosity Diagnostics (Warsaw, Poland), a wholly-owned subsidiary of Scope Fluidics S.A. More...
(Warsaw, Poland), the PCR|ONE SARS-CoV-2 panel is now CE-marked and can be introduced to the European market. The PCR|ONE SARS-CoV-2 panel uniquely combines several key parameters such as ease of use, affordable cost, very short testing time and informativeness.

Among all the rapid genetic tests for SARS-CoV-2, the PCR|ONE test is the most reliable method of detecting SARS-CoV-2 and also one the fastest on the market. A number of testing locations will benefit from the system’s unique performance, especially where fast and accurate diagnosis is important – from medical centers to any location frequented by the public.

The PCR|ONE system for SARS-CoV-2 virus detection successfully passed in-depth testing in external hospital laboratories, achieving very high values for the most relevant clinical parameters: 91.2% sensitivity and 100% specificity. On the other hand, in the analysis of samples containing higher amounts of viral RNA (samples from patients likely to infect other people), the PCR|ONE system proved flawless, obtaining 100% sensitivity and 100% specificity. PCR|ONE with the SARS-CoV-2 panel was also tested the PCR|ONE system at the Warsaw Chopin Airport, where passengers from almost all over the world arrive.

“PCR|ONE is designed to test for a number of targets in the SARS-CoV-2 genome,” said Vincent Linder, Ph.D., author of more than 300 patents in microfluidic techniques and point-of-care diagnostics, founder of a diagnostics startup at Harvard University, and member of the Scope Fluidics Board of Experts. “As such it can be easily adapted to include new genetic targets to timely address the threat posed by new variants of the virus. It is a system that has an enormous growth potential – as a powerful tool to fight the COVID-19 pandemic and also a number of other conditions where a timely diagnosis allows for rapid initiation of treatment and improvement in patient outcome.”

“We have demonstrated the versatility of the PCR|ONE system. We knew that it could be used to identify bacterial DNA along with checking their antibiotic susceptibility. Now we know that it can also be used to identify virtually any pathogen in the world. This will open way for a very broad application of the PCR|ONE system in medical diagnostics,” said Dr. Kamil Gewartowski, PCR|ONE project manager at Scope Fluidics.

Related Links:
Curiosity Diagnostics
Scope Fluidics S.A.



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.